Professor Emeritus of Radiology and Medcine
Oncology
Dr. Edward B. Silberstein, MD
|
|
Give Review
Edward Silberstein is an expert in the field of Oncology. He graduated from Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He has 1 awards "Whos Who in Medicine and Healthcare". Dr. Edward B. Silberstein is also published. He has 99 publications published. The lastest publication: "Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- The AEC/NRC Thirty-Millicurie Rule: Regulatory Origins and Clinical Consequences for Iodine-131 Remnant Ablative Dosages.
- Prevalence of Adverse Events to Radiopharmaceuticals from 2007 to 2011.
- The Timing of Pregnancy Testing in 131I Therapy.
- The SNMMI practice guideline for therapy of thyroid Disease with 131I 3.0.
- An alpha edge?
- The SNM practice guideline for somatostatin receptor scintigraphy 2.0.
- The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome.
- Clinical trials and socioeconomic implication in the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Pane...
- A closer look at the latest NRC patient release guidance.
- Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine.
- Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated Thyroid carcinoma.
- Bone mineral density (BMD) assessment of central skeletal sites from peripheral BMD and ultrasonographic measurements: an improved solution employing age and weight in...
- Radioiodine therapy and pregnancy.
- Teletherapy and radiopharmaceutical therapy of painful bone metastases.
- Radiopharmaceuticals for the palliation of painful bone metastases.
- Radiopharmaceutical issues.
- Whole body and partial body radiotherapy of advanced Cancer.
- The human lymphocyte as a radiobiological dosimeter after total body irradiation.
- Radiobiological evaluation of immigrants from the vicinity of Chernobyl.
- Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased intracellular hemoglobin concentration and decreased in vitro sickli...
- The in vivo survival of human red Cells with low oxygen affinity prepared by the osmotic pulse method of inositol hexaphosphate incorporation.
- Protein C deficiency resulting from possible double heterozygosity and its response to danazol.
- Treatment of Polycythemia vera with hydroxyurea.
- Time-dependent changes in the density and hemoglobin F content of biotin-labeled Sickle cells.
- Studies in red blood Cell preservation. 7. In vivo and in vitro studies with a modified phosphate-ammonium additive solution.
- Mucocele of the skull.
- Bacterial infectibility of chronically implanted endothelial Cell-seeded expanded polytetrafluoroethylene vascular grafts.
- A comparison between fibronectin and Matrigel pretreated ePTFE vascular grafts.
- The potential unreliability of indium 111 oxine labeling in studies of endothelial Cell kinetics.
- Increased gut blood flow with early enteral feeding in burned guinea pigs.
- Incidental finding of crossed renal ectopia diagnosed on bone scan.
- Intense uptake of In-111 satumomab pendetide in an inflammatory mass.
- Availability of radioisotopes produced in North America.
- Drug labeling changes.
- Gentisic acid: a new stabilizer for low tin skeletal imaging agents: concise communication.
- Still more applications of hepatobiliary scintigraphy.
- Clinical significance of serum vitamin B12 measured by radioassay using pure intrinsic factor.
- Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.
- Synthesis and renal excretion of technetium-99m-labeled organic cations.
- Visualization of alcohol-induced rhabdomyolysis: a correlative radiotracer, histochemical, and electron-microscopic study.
- Clinical comparison of technetium-99m diphosphonate and pyrophosphate in bone scintigraphy: concise communication.
- Causes of abnormalities reported in nuclear medicine testing.
- Assay of 32P-sodium phosphate.
- Motion-corrected hepatic scintigraphy.
- Gallium-67 in primary Lung carcinoma.
- Optimizing brain-scan sensitivity.
- Radioactivity variations in cobalt-57 cyanocobalamin capsules.
- Epidural hematoma with decreased radionuclide uptake.
- Value of 48- or 72-hr urine collections in performing the Schilling test.
- Isolated right superior vena cava draining into left atrium diagnosed by radionuclide angiocardiography.
- Letter: Calcium, phosphorus, 99mTc "uptake".
- 111-In-bleomycin kinetics in mice bearing transplantable tumors of Lung, skin, and bone.
- Reverse redistribution phenomenon in thallium-201 stress tests: angiographic correlation and clinical significance.
- Detection of clinically occult axillary metastases from Breast cancer during stress TI-201 scintigraphy.
- Fibrosing mediastinitis causing nonvisualization of one Lung on pulmonary scintigraphy.
- Calculating lens dose and surface dose rates from 90Sr ophthalmic applicators using Monte Carlo modeling.
- Incidental detection of obstructive uropathy during scrotal imaging.
- Clinical and radiographic correlates of femoral artery visualization on bone scan.
- Radionuclide therapy of hematologic disorders.
- Brain scintigraphy in the diagnosis of the sequelae of head trauma.
- The importance of the lateral view in Ga-67 citrate imaging of the thorax. Esophageal carcinoma.
- A radiopharmaceutical and clinical comparison of 99mTc-Sn-hydroxymethylene diphosphonate with 99mTc-Sn-hydroxyethylidene diphosphonate.
- Adverse reactions to radiopharmaceuticals: the SNM/RSNA USP Drug Product Problem Reporting Program. Society of Nuclear Medicine/Radiological Society of North America. ...
- Imaging of bone metastases with 99m Tc-Sn-EHDP (diphosphonate), 18 F, and skeletal radiography. A comparison of sensitivity.
- Tc-99m diphosphonate and sulfur colloid uptake by the spleen in Sickle disease: interrelationship and clinical correlates: concise communication.
- The value of hepatobiliary scans in fasted patients receiving total parenteral nutrition.
- Distribution of 99mTc-Sn diphosphonate and free 99mTc-pertechnetate in selected soft and hard tissues.
- Challenges in development and use of radiopharmaceuticals.
- Minimal bone scan findings in the presence of wide-spread osteoblastic Disease on skeletal radiography.
- Trends in American nuclear medicine training: past, present, and future.
- Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study.
- Bone scintigraphy screening in stage I-II Breast cancer: is it cost-effective?
- Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
- Strontium-89 therapy for the pain of osseous metastases.
- How to be an effective risk communicator.
- How to be an effective risk communicator--Part 1.
- Are oral cathartics of value in optimizing the gallium scan? Concise communication.
- Colorectal Cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments.
- The treatment of painful osseous metastases with phosphorus-32-labeled phosphates.
- Adverse reactions to radiopharmaceuticals: the RSNA-SNM-USP Drug Product Problem Reporting Program.
- The treatment of painful osteoblastic metastases: what can we expect from nuclear oncology?
- Painful osteoblastic metastases: the role of nuclear medicine.
- Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.
- Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases.
- Procedure guideline for gallium scintigraphy in the evaluation of malignant Disease. Society of Nuclear Medicine.
- Systemic radiopharmaceutical therapy of painful osteoblastic metastases.
- Radon update: facts concerning environmental radon: levels, mitigation strategies, dosimetry, effects and guidelines. SNM Committee on Radiobiological Effects of Ioniz...
- 201Tl as a tumour-localizing agent: current status and future considerations.
- Perfusion and ventilation scans in patients with extensive obstructive airway Disease: utility of single-breath (washin) xenon-133.
- Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
- Cyclic oral phosphate and etidronate increase femoral and lumbar bone mineral density and reduce lumbar spine fracture rate over three years.
- Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
- Procedure guideline for bone pain treatment: 1.0. Society of Nuclear Medicine.
- EANM procedure guidelines for treatment of refractory metastatic bone pain.
- Procedure guideline for therapy of thyroid Disease with (131)iodine.
- The US national isotope program: current status and strategy for future success.
- Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
- Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology.
Schools
Harvard Medical School
University Cincinnati Hospital
University Hosps
New England Med Center
Conditions Treated
- Anemia
- Breast Cancer
- Lung Cancer
- Melanoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Whos Who in Medicine and Healthcare
Education
-
Tufts Medical Center -
Case Western Reserve University - University Hospitals -
University Hospital - University of Cincinnati College of Medicine -
Harvard Medical School
Hospital
-
University of Cincinnati Medical Center
Drug Facts
| NPI NUMBER | 1831205889 | |
| NPPES Provider LastName | SILBERSTEIN | |
| NPPES Provider FirstName | EDWARD | |
| NPPES Provider ZIPCode | 452192364 | |
| NPPES Provider State | OH | |
| Specialty Description | Nuclear Medicine | |
| Total Claim Count | 360.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1831205889 |
| Last Name Of The Provider | SILBERSTEIN |
| First Name Of The Provider | EDWARD |
| View All |
Similar Doctors
|
|
Dr. Irfan Firdaus, DO
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James H. Essell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jamie K. Waselenko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark Andolina, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shaili Desai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanne M. Partridge, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph E. Palascak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose G. Barreau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sajini Mathew, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Apurva C. Mehta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Morris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hyon J. Kim, MD |